- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00548834
Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
September 3, 2013 updated by: UCB Pharma
Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
220
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male/female, 18-75 years old, inclusive
- diagnosis of adult-onset RA
- had active disease
- had received methotrexate
- on a stable dose of folic acid
Exclusion Criteria:
- contraindication for methotrexate or anti-TNF
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
American College of Rheumatology (ACR)-20 responder rate at Week 24
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety and tolerability every 4 weeks
Time Frame: Every 4 weeks
|
Every 4 weeks
|
effect of CDP870 on health outcomes measures
Time Frame: 24 weeks
|
24 weeks
|
systemic exposures and immunogenic profile of CDP870
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2003
Primary Completion (Actual)
July 1, 2004
Study Completion (Actual)
July 1, 2004
Study Registration Dates
First Submitted
October 15, 2007
First Submitted That Met QC Criteria
October 23, 2007
First Posted (Estimate)
October 24, 2007
Study Record Updates
Last Update Posted (Estimate)
September 4, 2013
Last Update Submitted That Met QC Criteria
September 3, 2013
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C87011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on CDP870
-
Otsuka Pharmaceutical Co., Ltd.UCB Japan Co. Ltd.Completed
-
UCB PharmaCompletedCrohn's DiseaseUnited States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
-
UCB Pharma SACompletedCrohn's DiseaseUnited States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
-
UCB Pharma SACompletedCrohn's DiseaseUnited States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
-
UCB PharmaCompletedCrohn DiseaseUnited States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
-
Otsuka Pharmaceutical Co., Ltd.UCB Japan Co. Ltd.Completed
-
UCB CelltechTerminatedCrohn's DiseaseUnited States, Canada, New Zealand, Australia
-
UCB PharmaCompletedRheumatoid ArthritisPoland, Germany, Austria, France, Italy
-
UCB BIOSCIENCES GmbHPPDCompletedCrohn DiseaseRussian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
-
UCB PharmaCompleted